Its position in the PI3K/AKT/mTOR pathway has made it a potential therapeutic target, and mTOR inhibitors, such as rapamycin, have been used to treat a variety of conditions and various other non-cSCC cancers [75]. The gene discussed is AKT1; the disease is cancer.